Joerger, M <br/><br/>
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  10 2016 
 - 1895-902 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdw290  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Carboplatin--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cisplatin--administration & dosage<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Drug-Related Side Effects and Adverse Reactions--classification<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Paclitaxel--administration & dosage